NO20084619L - Legemiddel i form av mikropartikler - Google Patents

Legemiddel i form av mikropartikler

Info

Publication number: NO20084619L
Authority: NO; Norway
Prior art keywords: microparticles; drug; carrier material; material particles; inhalation
Prior art date: 2006-04-03

Application number

NO20084619A

Other languages

English (en)

Norwegian (no)

Inventor

Moshe Flashner-Barak

E Itzhak Lerner

Roud Smit

Richard Van Lamoen

Erwin V Achthoven

Hans Keegstra

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-03

Filing date

2008-10-31

Publication date

2008-12-16

2008-10-31 Application filed by Teva Pharma filed Critical Teva Pharma

2008-12-16 Publication of NO20084619L publication Critical patent/NO20084619L/no

Links

239000003814 drug Substances 0.000 title abstract 3
229940079593 drug Drugs 0.000 title abstract 3
239000011859 microparticle Substances 0.000 title abstract 3
239000012876 carrier material Substances 0.000 abstract 2
239000002245 particle Substances 0.000 abstract 2
201000003883 Cystic fibrosis Diseases 0.000 abstract 1
208000032376 Lung infection Diseases 0.000 abstract 1
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 abstract 1
229960005084 calcitriol Drugs 0.000 abstract 1
235000020964 calcitriol Nutrition 0.000 abstract 1
239000011612 calcitriol Substances 0.000 abstract 1
238000002347 injection Methods 0.000 abstract 1
239000007924 injection Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
238000000859 sublimation Methods 0.000 abstract 1
230000008022 sublimation Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Otolaryngology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20084619A 2006-04-03 2008-10-31 Legemiddel i form av mikropartikler NO20084619L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US78919706P	2006-04-03	2006-04-03
US85477806P	2006-10-26	2006-10-26
PCT/US2007/008685 WO2007117661A2 (en)	2006-04-03	2007-04-03	Drug microparticles

Publications (1)

Publication Number	Publication Date
NO20084619L true NO20084619L (no)	2008-12-16

Family

ID=38581674

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20084619A NO20084619L (no)	2006-04-03	2008-10-31	Legemiddel i form av mikropartikler

Country Status (12)

Country	Link
US (1)	US20080057129A1 (de)
EP (1)	EP2010153A2 (de)
JP (1)	JP2009532489A (de)
KR (1)	KR20080105174A (de)
BR (1)	BRPI0709872A2 (de)
CA (1)	CA2647073A1 (de)
IL (1)	IL194095A0 (de)
MX (1)	MX2008012794A (de)
NO (1)	NO20084619L (de)
RU (1)	RU2008142388A (de)
TW (1)	TW200817047A (de)
WO (1)	WO2007117661A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0327723D0 (en)	2003-09-15	2003-12-31	Vectura Ltd	Pharmaceutical compositions
CA2615173C (en)	2005-07-14	2012-01-03	Lipothera, Inc.	Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
US8415390B2 (en)	2008-05-30	2013-04-09	Microdose Therapeutx, Inc.	Methods and compositions for administration of oxybutynin
US9119777B2 (en)	2008-05-30	2015-09-01	Microdose Therapeutx, Inc.	Methods and compositions for administration of oxybutynin
WO2009064469A1 (en) *	2007-11-14	2009-05-22	Nektar Therapeutics	Pulmonary delivery of a macrolide antibiotic
EP2296628B1 (de)	2008-05-22	2014-05-14	3M Innovative Properties Company	Verfahren zur herstellung von fliessfähigen pulverförmigen arzneimittelzusammensetzungen
US9956170B2 (en)	2008-06-26	2018-05-01	3M Innovative Properties Company	Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof
EP2174654B1 (de) *	2008-10-09	2012-08-22	Bobelium, S.L.	Mikronisierte Zusammensetzung aus 2,4,6-Triiodophenol
US8168597B2 (en) *	2008-10-22	2012-05-01	Inspire Pharmaceuticals, Inc.	Method for treating cystic fibrosis
CA2750711C (en)	2009-01-26	2015-07-07	Teva Pharmaceutical Industries Ltd.	Processes for coating a carrier with microparticles
US20100285164A1 (en) *	2009-05-11	2010-11-11	Jrs Pharma	Orally Disintegrating Excipient
US9132084B2 (en)	2009-05-27	2015-09-15	Neothetics, Inc.	Methods for administration and formulations for the treatment of regional adipose tissue
GB2487868B (en) *	2010-01-15	2014-12-10	Neothetics Inc	Lyophilized cake formulations
WO2011121425A1 (en) *	2010-03-31	2011-10-06	Glenmark Pharmaceuticals Limited	Pharmaceutical powder composition for inhalation
US10842770B2 (en)	2010-05-03	2020-11-24	Teikoku Pharma Usa, Inc.	Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
EP2621588A4 (de) *	2010-09-27	2014-09-03	Microdose Therapeutx Inc	Verfahren und zusammensetzungen zur krankheitsbehandlung durch inhalation
UA111822C2 (uk)	2010-11-24	2016-06-24	Общєство С Огранічєнной Отвєтствєнностью "Новамедіка"	Монотерапевтичий препарат селективного ліпофільного бета-агоніста тривалої дії і спосіб косметичного лікування ожиріння і контурного випинання
BR112013026313A8 (pt) *	2011-04-12	2018-01-30	Moerae Matrix Inc	composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular
US9890200B2 (en) *	2011-04-12	2018-02-13	Moerae Matrix, Inc.	Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US9572774B2 (en)	2011-05-19	2017-02-21	Savara Inc.	Dry powder vancomycin compositions and associated methods
JP5981123B2 (ja) *	2011-10-11	2016-08-31	サンサコーポレーション（バルバドス）インク	ニコチン薬の製造法およびその方法により製造される医薬
EP2872121B1 (de)	2012-07-12	2018-09-05	SpecGx LLC	Missbrauchssichere pharmazeutische zusammensetzungen mit verzögerter freisetzung
JO3685B1 (ar)	2012-10-01	2020-08-27	Teikoku Pharma Usa Inc	صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
MX2015006457A (es) *	2012-11-30	2015-08-14	Hoffmann La Roche	Inhibidores de la tirosina cinasa de bruton.
HUE050050T2 (hu) *	2013-03-04	2020-11-30	Besins Healthcare Lu Sarl	Hordozórészecskékhez kötõdõ hatóanyag nanorészecskéket tartalmazó száraz gyógyászati kompozíciók
GB201321717D0 (en) *	2013-12-09	2014-01-22	Pharmachemie Bv	Inhalable Medicaments
GB201402513D0 (en) *	2014-02-13	2014-04-02	Cardiff Scintigraphics Ltd	Pressurised metered dose inhalers and method of manufacture
US20220105286A1 (en) *	2014-02-13	2022-04-07	Cardiff Scintigraphics Limited	Pressurized metered dose inhalers and method of manufacture
RU2713953C2 (ru) *	2014-07-18	2020-02-11	Аллерган, Инк.	Суспензионные составы циклоспорина а для субконъюнктивального и периокулярного введения
FR3039990B1 (fr)	2015-08-10	2018-07-06	Rhodia Operations	Procede d'encapsulation
WO2017147420A1 (en) *	2016-02-25	2017-08-31	The University Of Florida Research Foundation, Inc.	Methods and compositions with vitamin d compounds for treatment of cystic fibrosis and respiratory disorders
WO2018231908A1 (en)	2017-06-14	2018-12-20	Crititech, Inc.	Methods for treating lung disorders
US20200237867A1 (en) *	2017-10-12	2020-07-30	Board Of Regents, The University Of Texas System	Methods and devices for promoting nerve growth and regeneration
EP3833329A1 (de)	2018-08-06	2021-06-16	Khan, Khalid	Antimikrobielle formulierungen mit vancomycin oder tobramycin
AU2021221987B2 (en) *	2020-02-19	2026-02-12	Nano Pharmasolutions, Inc.	Therapeutic agent nanoparticles and methods of preparation
EP4132484A1 (de) *	2020-04-10	2023-02-15	Galenus G.H. AG	Zusammensetzung mit resveratrol
US20240000717A1 (en) *	2020-11-19	2024-01-04	Nano Pharmasolutions, Inc.	Dry powder antiviral compositions and their use for treating viral infection
CA3211799A1 (en) *	2021-03-12	2022-09-15	Robert O. Williams Iii	Methods to prepare dry powders using suspension based thin film freezing

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5429566B2 (de) *	1974-09-13	1979-09-25
NL8600731A (nl) *	1986-03-21	1987-10-16	Dmv Campina Bv	Verbeterde gesproeidroogde lactose en werkwijze ter bereiding ervan.
US5342625A (en) *	1988-09-16	1994-08-30	Sandoz Ltd.	Pharmaceutical compositions comprising cyclosporins
US6060069A (en) *	1991-05-20	2000-05-09	Dura Pharmaceuticals, Inc.	Pulmonary delivery of pharmaceuticals
GB9622173D0 (en) *	1996-10-24	1996-12-18	Glaxo Group Ltd	Particulate Products
AU5719798A (en) *	1996-12-31	1998-07-31	Inhale Therapeutic Systems, Inc.	Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
RU2202340C2 (ru) *	1998-05-27	2003-04-20	Юроселтик С.А.	Система доставки лекарства
SE9803240D0 (sv) *	1998-09-24	1998-09-24	Diabact Ab	A pharmaceutical composition having a rapid action
US6294192B1 (en) *	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
IT1309592B1 (it) *	1999-03-05	2002-01-24	Chiesi Farma Spa	Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
US6369115B1 (en) *	2000-03-20	2002-04-09	Dura Pharmaceuticals, Inc.	Stabilized powder formulations
CN1461210A (zh) *	2000-09-20	2003-12-10	尼库麦德制药As	乳剂及其浓缩物的制备
HRP20010301A2 (en) *	2001-04-27	2001-12-31	Pliva D D	New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
BR0212833A (pt) *	2001-09-26	2004-10-13	Baxter Int	Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
GB0201400D0 (en) *	2002-01-22	2002-03-13	Glaxo Group Ltd	Novel apparatus and process
KR20040098023A (ko) *	2002-03-26	2004-11-18	테바 파마슈티컬 인더스트리즈 리미티드	약물 미세입자
EP1553954A4 (de) *	2002-06-17	2009-12-23	Epigenesis Pharmaceuticals Llc	Dihydrat-dehydroepiandrosteron und verfahren zur behandlung von asthma oder chronisch obstruktiver lungenerkrankung mit zusammensetzungen daraus
US20040105821A1 (en) *	2002-09-30	2004-06-03	Howard Bernstein	Sustained release pharmaceutical formulation for inhalation
AU2003205499A1 (en) *	2003-02-28	2004-09-17	Anbics Patents-Licences Ag	Method for treatment and prevention of acute and chronic pseudomonas aeruginosa airway infections with inhalable macrolides
DE602004012440T2 (de) *	2003-11-21	2009-03-26	Galderma Research & Development	Sprühbare zusammensetzung zur verabreichung von vitamin d derivaten

2007
- 2007-04-03 EP EP07755077A patent/EP2010153A2/de not_active Withdrawn
- 2007-04-03 US US11/732,705 patent/US20080057129A1/en not_active Abandoned
- 2007-04-03 CA CA002647073A patent/CA2647073A1/en not_active Abandoned
- 2007-04-03 BR BRPI0709872-3A patent/BRPI0709872A2/pt not_active IP Right Cessation
- 2007-04-03 MX MX2008012794A patent/MX2008012794A/es not_active Application Discontinuation
- 2007-04-03 JP JP2009504340A patent/JP2009532489A/ja active Pending
- 2007-04-03 KR KR1020087026413A patent/KR20080105174A/ko not_active Ceased
- 2007-04-03 WO PCT/US2007/008685 patent/WO2007117661A2/en not_active Ceased
- 2007-04-03 RU RU2008142388/15A patent/RU2008142388A/ru unknown
- 2007-04-03 TW TW096111920A patent/TW200817047A/zh unknown
2008
- 2008-09-15 IL IL194095A patent/IL194095A0/en unknown
- 2008-10-31 NO NO20084619A patent/NO20084619L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
IL194095A0 (en)	2009-08-03
WO2007117661A3 (en)	2008-01-17
WO2007117661A2 (en)	2007-10-18
JP2009532489A (ja)	2009-09-10
TW200817047A (en)	2008-04-16
EP2010153A2 (de)	2009-01-07
CA2647073A1 (en)	2007-10-18
RU2008142388A (ru)	2010-05-10
MX2008012794A (es)	2008-10-15
US20080057129A1 (en)	2008-03-06
BRPI0709872A2 (pt)	2011-07-26
KR20080105174A (ko)	2008-12-03

Legal Events

Date	Code	Title	Description
2011-11-28	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20084619L (no)	2008-12-16	Legemiddel i form av mikropartikler
WO2010047765A8 (en)	2011-05-05	Nanostructures for drug delivery
TNSN07341A1 (en)	2008-12-31	Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
CY1125382T1 (el)	2025-05-09	Συνθεση για εισπνοη που περιεχει ακλιδινιο για τη θεραπευτικη αντιμετωπιση του ασθματος
CA2801936C (en)	2021-06-01	Dry powder drug delivery system and methods
WO2015054124A3 (en)	2015-09-03	Dry powder inhaler
EP4393491A3 (de)	2024-07-24	Verfahren zur behandlung von pulmonaler mykobakterieller nicht-tuberkuloser infektionen
WO2007149406A3 (en)	2008-07-10	Modified coagulation factor ix polypeptides and use thereof for treatment
CY1106269T1 (el)	2011-10-12	Σωματιδια σκονης με λεια επιφανεια για χρηση σε θepαπεια με εισπνοη
NO20083863L (no)	2008-12-03	Pyrazoler som 11-beta-hsd-1
TW200640908A (en)	2006-12-01	Chemical compounds
MY141025A (en)	2010-02-25	Dose forms
NO20090469L (no)	2009-03-27	Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
WO2006086107A3 (en)	2006-11-23	Methods and compositions for minimizing accrual of inhalable insulin in the lungs
WO2009029622A3 (en)	2009-04-23	Antiviral drugs for treatment of arenavirus infection
BRPI0516262A (pt)	2008-08-26	métodos e kits para distribuir fármacos por nebulização
EA201170527A1 (ru)	2011-10-31	Фармацевтические композиции, включающие соединения бороновой кислоты
MX2013013503A (es)	2014-05-12	Composiciones de vancomicina en polvo seco y metodos asociados.
MX2009012598A (es)	2009-12-07	Formas de dosis que comprenden vx-950 y su regimen de dosificacion.
BR112014008609A2 (pt)	2017-04-18	composição farmacêutica, recipiente vedado, inalador de dosagem medida, método para o tratamento de um paciente que sofre ou provavelmente sofre de um distúrbio respiratório, e, método para fabricação de uma composição farmacêutica
NO20074084L (no)	2007-09-28	Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikamenter og medikamenter inneholdende disse
CL2007003754A1 (es)	2008-08-22	Compuestos derivados de aril(heteroaril)alquil-amina; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como bronquitis, enfisema pulmonar y epoc.
HK1245125A1 (zh)	2018-08-24	包含丙酸氟替卡松和昔萘酸沙美特罗的干粉吸入器
NO20082396L (no)	2008-08-26	Fremgangsmater for behandling av mave-tarmkanalinfeksjoner med tigecyclin
NO20065936L (no)	2007-02-19	Sulfonyletylfosfordiamidater for anvendelse ved behandling av cancer.